Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
ABBV
AbbVie
$230.50
Login to see AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Investors confidence is positive
Pays a reliable dividend
Chart
$216.29 (+6.57%)
$184.85 (+24.70%)
$181.8 (+26.79%)
$187.85 (+22.70%)
ABBV has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
ABBV overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Revenue increase YoY
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Trading below its fair value
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayABBV Earnings
The TTM reflects 12-month period, providing review of ABBV financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
PFE
24.78
-1.82%
NVS
130.03
-0.81%
LLY
833.49
-2.56%
SNY
48.09
-1.50%
ABT
132.57
-0.56%
What is ABBV current stock price?
What are ABBV stock strengths?
What risks are associated with ABBV stock?
When is ABBV next earnings report?
What is ABBV market cap and volume?
What is ABBV's current Stock IQ?
Should I buy ABBV stock right now?
Is ABBV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABBV?
What does a 'Strong Sell' rating mean for ABBV?
What factors influence ABBV's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
ABBV
AbbVie
Current Price
$230.50
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Investors confidence is positive
Pays a reliable dividend
Linked to ABBV
PFE
24.78
-1.82%
NVS
130.03
-0.81%
LLY
833.49
-2.56%
SNY
48.09
-1.50%
ABT
132.57
-0.56%
Login to unlock AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$216.29 (+6.57%)
$184.85 (+24.70%)
$181.8 (+26.79%)
$187.85 (+22.70%)
ABBV Analysts Opinion
ABBV Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Revenue increase YoY
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Trading below its fair value
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
ABBV has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
Average key support and resistance price levels.
Login to displayABBV Earnings
The TTM data reflects the most recent 12-month period, providing overview of ABBV financial performance.
ABBV Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
ABBV Latest Analysis
Carolina Wealth Trims Its AbbVie Stake to Nearly Nothing. Key PointsCarolina Wealth Advisors sold 38267 AbbVie shares. estimated transaction value ~$7.79 million based on quarterly average price
Thu Oct 9, 2025
Cantor Fitzgerald raises Abbvie stock price target to $250 on strong Skyrizi performance.
Thu Oct 9, 2025
Cramers Absolute Favorite AbbVie Rises After Study Completions and Upgrade. AbbVie Inc. (NYSE:ABBV) is one of Jim Cramers Recession-Proof Stock Picks. Cramer calls the stock his absolute favorite and it is followed by updates on the completion of two key studies. At the beginning of this month AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101s food interaction and a Phase 2 [….]
Wed Oct 8, 2025
AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester Massachusetts. With significant hedge fund interest and trending on Reddit AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. As part of its $10 billion United States capital expenditure strategy to increase biologics manufacturing capacity AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its [….]
Wed Oct 8, 2025
3 Dividend Stocks to Double Up On Right Now. Key PointsAbbVie is a Dividend King with solid growth prospects.
Tue Oct 7, 2025
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?. ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizers landmark drug-pricing deal with the Trump administration.
Mon Oct 6, 2025
AbbVies Botox Shows Improvement In Movement Disorder Study. ) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper .Upper limb essential tremor is a progressive movement disorder characterized by rhythmic involuntary shaking of the hands and arms most pronounced during action or specific postures.The study met its primary endpoint demonstrating statistically significant improvements in the Tremor Disability Scale-Revise
Mon Oct 6, 2025
AbbVie succeeds in mid-stage study of Botox for essential tremor.
Mon Oct 6, 2025
AbbVie Says Phase 2 ELATE Trial Met Primary Endpoint For BOTOX To Treat Upper Limb Essential Tremor . (RTTNews) - AbbVie Inc. (ABBV) announced Monday positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX) compared to placebo for the treatment of upper limb essential tremor.
Mon Oct 6, 2025
B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation. Fintel reports that on October 3 2025 B of A Securities maintained coverage of AbbVie (NYSE:ABBV) with a Neutral recommendation. Analyst Price Forecast Suggests 1.77% Downside
Fri Oct 3, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders